NRG Therapeutics is leveraging breakthrough science in the field of mitochondrial biology to identify new therapeutic targets to treat neurodegenerative disorders.

We are developing novel ‘next generation’ mitochondrial permeability transition pore (mPTP) inhibitors that are orally bioavailable and brain-penetrant. These inhibitors prevent the mitochondrial gain-of-function toxicity of misfolded TDP-43 and α-synuclein, the pathological proteins that cause the degeneration of motor neurones and dopaminergic neurones in ALS and Parkinson’s respectively. The company benefits from the drug discovery and neuroscience expertise and insights, and biotech experience of its founders, its management team and expert advisors, and world-leading scientific and drug development collaborators.